Investigating Combinations in Recurrent or Metastatic Cervical Cancer

July 02, 2020

Bradley Monk, MD, discusses the phase 1b/2 innovaTV 205 trial in patients with recurrent or metastatic cervical cancer.

Novel BTK Inhibitor Appears Promising in Mantle Cell Lymphoma and Other NHLs

July 02, 2020

In an interview with Targeted Oncology, Gaël Roué, PhD, discussed the rationale for evaluating TG-1701 in combination with ublituximab and umbralisib in ibrutinib-resistant MCL.

Cemiplimab Upholds Efficacy in 3-Year Follow-up for Advanced Cutaneous Squamous Cell Carcinoma

July 01, 2020

In an interview with Targeted Oncology, Danny Rischin, MD, director, discussed the findings from the EMPOWER-CSCC-1 study of cemiplimab in advanced cutaneous squamous cell carcinoma that led to the drug’s FDA approval.

FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid Cancer

July 01, 2020

"Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted therapy even though their tumors have a known disease driver."

Positive Tepotinib Data Underscore Value of Liquid Biopsies in Non-Small Cell Lung Cancer

July 01, 2020

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.

Avelumab Approved by FDA for the Treatment of Locally Advanced Urothelial Carcinoma

July 01, 2020

The FDA approved avelumab as a frontline maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma who have not progressed with frontline platinum-based chemotherapy.

Trastuzumab Added to Chemotherapy Improves Survival in Uterine Serous Carcinoma

July 01, 2020

The addition of trastuzumab to chemotherapy in patients with uterine serous carcinoma had superior outcome compared with chemotherapy alone.

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

July 01, 2020

Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 01, 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

A Look Back at the FDA News from June 2020

July 01, 2020

Here is a look back at the FDA happenings from the month of June 2020.